1. Introduction {#sec1}
===============

Visceral leishmaniasis (VL) is a neglected tropical disease (NTD) caused by *Leishmania infantum* and *L. donovani*, and fatal if left untreated. The available treatments all have considerable drawbacks, such as toxicity, teratogenicity and decreasing efficacy as noted by increasingly frequent treatment failures and the occurrence of drug resistance ([@bib5]). New drugs with higher efficacy and especially lower toxicity are needed to enable a continued fight against this disease. Drugs for Neglected Diseases *initiative* (DND*i*) is a not-for-profit organization that focuses on lead discovery and development of new drugs against NTDs ([@bib2], [@bib12], [@bib21]). A novel aminopyrazole lead series with promising antileishmanial potential was recently identified ([@bib22]) as well as a bicyclic nitroimidazole and oxaborole series for which the structure activity/property relationship studies are still ongoing.

Regarding nitro-aromatic drugs in general, these are already widely used against several parasite protozoan infections, including giardiasis, trichomoniasis and amoebiasis ([@bib29], [@bib13]). Against kinetoplastids, nifurtimox and benznidazole are used for treatment of Chagas disease ([@bib25]), while a combination therapy based on eflornithine and nifurtimox shows good efficacy and lower toxicity in human African trypanosiomiasis (HAT) ([@bib28]). Fexinidazole is yet another example with activity in Chagas ([@bib1]), and VL ([@bib39]). Two new bicyclic nitroimidazoles DNDI-VL-2098 ([@bib23]) and DNDI-0690 showing promising activity against VL have progressed towards preclinical development ([@bib26]). Initially identified for their antifungal potential ([@bib31]), oxaboroles have been shown to be effective for the treatment of HAT ([@bib24], [@bib38]). SCYX-7158 entered phase-II/III for HAT while DNDI-6148 more recently became a drug development candidate for VL. Aminopyrazoles are now in late lead optimization phase for leishmaniasis ([@bib22]) and were previously explored for cancer treatment ([@bib27], [@bib30]).

The aim of the present study was threefold: i) evaluate the *in vitro* and *in vivo* activity profile of the selected nitroimidazole, oxaborole and aminopyrazole lead compound(s) against a panel of visceral *Leishmania* strains, ii) assess potential cross-resistance with the current antileishmanial drugs and iii) characterize whether they have leishmanicidal potential.

2. Materials and methods {#sec2}
========================

2.1. Ethics statement {#sec2.1}
---------------------

The use of laboratory rodents was carried out in strict accordance to all mandatory guidelines (EU directives, including the Revised Directive, 2010/63/EU on the Protection of Animals used for Scientific Purposes that came into force on 01/01/2013, and the declaration of Helsinki in its latest version) and was approved by the Ethical Committee of the University of Antwerp, Belgium \[UA-ECD 2011--77\].

2.2. Animals {#sec2.2}
------------

Female Swiss mice (15--20g) and female golden hamsters (80--100 g) were purchased from Janvier (Le Genest Saint Isle, France). Food for laboratory rodents (Carfil, Arendonk, Belgium) and drinking water were available *ad libitum*. The animals were kept in quarantine for at least 5 days before infection and were randomly allocated to the experimental units.

2.3. Test substances {#sec2.3}
--------------------

Miltefosine (MIL), paromomycin (PMM) and potassium antimonyl tartrate (Sb^III^) were purchased from Sigma Aldrich (Diegem, Belgium); sodium stiboglucanate (Sb^V^) was obtained from Calbiochem (EMD Millipore Corporation, MA, USA); amphotericin B (AmB, Fungizone^®^) was obtained from Bristol-Myers-Squib (Gilead Sciences, CA, USA). The lead compounds ([Table S1](#appsec1){ref-type="sec"}) in the nitroimidazole, oxaborole and aminopyrazole chemical series were selected after a SAR analysis and provided by DND*i* (Geneva, Switzerland). Stock solutions for the *in vitro* assays were prepared in PBS for MIL (20 mM) and Sb (5.12 mg/mL) and in demineralized water for PMM (20 mM). AmB stock solutions (5.4 mM) were freshly prepared in 5% dextrose. Stock solutions (20 mM) of the DND*i* lead compounds were prepared in DMSO and stored at 4 °C until use. Stock solutions were further diluted in demineralized water, except for DNDI-6148 that was diluted in 0.25% methylcellulose in water. In the *in vitro* assays, the final in-test concentration of DMSO was \<1%.

2.4. *In vitro* cytotoxicity assay on MRC-5 cells {#sec2.4}
-------------------------------------------------

MRC-5~SV2~ cells were cultured in MEM with Earl\'s salts-medium (Life Technologies) supplemented with L-glutamine, NaHC0~3~ and 5% inactivated fetal bovine serum (iFCS, Life Technologies). For the cytotoxicity assay, the cells were seeded at a concentration of 15,000 cells/well and 4-fold compound dilutions were added with a highest in-test concentration of 200 μM. After 3 days incubation at 37 °C and 5% CO~2~, resazurin (Sigma Aldrich, Diegem, Belgium) was added for fluorescence reading (Tecan^®^, GENios) after another 4 h of incubation. Cell viability was compared to the untreated control wells and the cytotoxic concentration 50% (CC~50~) was calculated of each compound.

2.5. Intracellular amastigote susceptibility assay {#sec2.5}
--------------------------------------------------

To obtain primary peritoneal macrophages, Swiss mice were stimulated by intraperitoneal injection of 1 mL 2% starch in PBS 48h prior to cell collection. Animals were euthanized with a CO2 overdose and upon removal of the skin, 10 mL of RPMI-1640 (Life Technologies) was injected into the peritoneal cavity to collect the macrophages that were then seeded into 96-well plates at a final concentration of 30,000 cells/well in 100 μL of RPMI-1640 macrophage medium, supplemented with 5% iFCS, 2% penicillin/streptomycin and 1% L-glutamine (Life technologies). After 24h, the cells were infected with spleen-derived *L. infantum* (MHOM/MA/67/ITMAP263) or *L. donovani* (MHOM/ET/67/L82) amastigotes obtained from heavily infected donor hamsters. The amastigotes were purified using two centrifugation steps and diluted to obtain an infection ratio of 5:1 in RPMI-1640 cell culture medium. After incubation for 2h, compound dilutions were added. Drug activity was evaluated after a 96-h incubation period without washing of the cells and without renewal of the drugged culture medium. Cells were stained with Giemsa for microscopic evaluation of cellular amastigote burdens. Percentage reduction compared to the burdens in the infected non-treated control wells was used as a measure for drug activity.

2.6. Cross-resistance with current antileismanial drugs {#sec2.6}
-------------------------------------------------------

An overview of the *L. infantum* strains with their origin and corresponding susceptibility profile to Sb^V^, Sb^III^, MIL and PMM is presented in [Table 1](#tbl1){ref-type="table"}. Promastigotes were cultured at room temperature in HOMEM promastigote medium (Gibco^®^, Life technologies), supplemented with 10% FCS. Infection of macrophages was carried out with metacyclic promastigotes at 15:1 multiplicity of infection. Infected macrophages were incubated at 37 °C and 5% CO~2~ and DND*i* compound dilutions were added 24h later. Drug susceptibility was determined microscopically after 96-h incubation without washing of the cells and without renewal of the drug-supplemented culture medium.Table 1Origin and susceptibility profile of selected *L. infantum* strains for the evaluation of cross resistance.Table 1*L. infantum*Susceptibility profileCountryOriginSb^V^Sb^III^MILPMMITMAP263SSSSMaltaReference lab strainL3034**RI**SSParaguayHIV-positive patientLEM5695SSSSFranceDogLEM5159SS**R**SFranceHIV-positive patient, failure AmBLEM3323 Cl4**RR**SSFranceHIV-positive patient, failure AmBLEM3323 Cl4 PMM**RR**S**R**FranceSelected for PMM resistanceLEM3323 Cl4 MIL**RRR**SFranceSelected for MIL resistance[^1]

2.7. Time-to-kill {#sec2.7}
-----------------

The time to kill (TTK) assay was performed to evaluate the minimal exposure time needed for the selected compounds to eliminate all viable intracellular parasites ([@bib19]). Briefly, macrophages were exposed to compound 24h after infection with *ex vivo* spleen-derived amastigotes of either *L. infantum* or *L. donovani* and the initial infection burdens were assessed 24h later. Drug exposure with the DND*i* lead compounds and the reference drugs MIL, PMM, Sb^V^ and AMB was set at 5 × IC~50~. Every 3 days, the medium was replaced with fresh drug-supplemented medium to assure optimal cell viability and drug exposure during the 15-day post-infection follow-up period. TTK was evaluated every 24h until 360h post-treatment primarily by staining a 96-well plate with Giemsa to determine the residual intracellular amastigote burden and using a duplicate plate for the promastigote back-transformation assay to assess viability of residual stages. Briefly, infected macrophages were mechanically disrupted after replacing the medium with HOMEM and incubated for 3 weeks at room temperature allowing residual viable amastigotes to transform back into promastigotes ([@bib15]). TTK was defined as the time required to achieve \>95% reduction in parasite burdens determined by Giemsa staining and absence of promastigote back transformation. For each time point, parasite burdens were compared with the non-treated culture running in parallel ([Fig. S1](#appsec1){ref-type="sec"}).

2.8. *In vivo* efficacy in the early curative treatment scheme {#sec2.8}
--------------------------------------------------------------

Spleen-derived amastigotes (see above) were used for artificial infection of Syrian golden hamsters that were randomly allocated to experimental units of 5 animals each. Individual body weights were measured at the start of the experiment. The infection inoculum containing 2 × 10^7^amastigotes/100 μl in was delivered by intracardial injection. The aminopyrazoles were formulated in 1% (w/v) methylcellulose (4000 cps) and 5% (v/v) Tween~80~ in water. Oxaboroles were prepared in ethanol (2% of total volume), followed by the addition of 1N NaOH (1.0 eq.) and finally diluted in 5% dextrose in water. Nitroimidazoles were formulated in 100% PEG~400~ and MIL was formulated in water. A vehicle control group was incorporated for each formulation type. All animals in each experimental unit were orally treated for 5 consecutive days starting at 21 days post-infection (dpi) ([@bib9]). The standard dose was 50 mg/kg s.i.d. or b.i.d. (dependent on the PK properties) to assure maximal exposure in the primary evaluation. Subsequently, a dose-titration was performed to determine the minimal effective dose. For close analogues in the series, the starting dose was not necessarily 50 mg/kg. Amastigote burdens in the target organs liver, spleen and bone-marrow were determined 10 days after end of treatment. The liver and spleen of individual animals were weighed and impression smears were stained with Giemsa for microscopic enumeration of the average number of amastigotes per cell by counting a minimum of 500 nuclei. The results are expressed as Leishman-Donovan Units (LDU) ([@bib10]). As the bone-marrow could not be weighed, amastigote burdens on the smears are not fully quantitative and percentage reduction should be interpreted accordingly.

3. Results {#sec3}
==========

3.1. *In vitro* cytotoxicity and drug susceptibility {#sec3.1}
----------------------------------------------------

Bicyclic nitroimidazoles and aminopyrazoles showed potent and selective activity in the sub-micromolar range against both *L. infantum* and *L. donovani* while oxaboroles showed slightly higher IC~50~-values. Overall, all tested lead compounds ([Table S1](#appsec1){ref-type="sec"}) except DNDI-5421 showed better activity and lower cytotoxicity than MIL ([Table 2](#tbl2){ref-type="table"}).Table 2**Overview of the *in vitro* susceptibility of the DND*i*-compounds in the intracellular amastigote assay against laboratory strains of *L. infantum* and *L. donovani***. Results are expressed as the mean IC~50~ (μM) ± standard error of mean (SEM) and are based on two independent replicates run in duplicate (n = 4).Table 2SeriesCompound*L. infantumL. donovani*Cytotoxicity (MRC-5)ReferenceMiltefosine3.50 ± 0.401.80 ± 0.4038.5 ± 4.18NitroimidazolesDNDI-06900.17 ± 0.020.16 ± 0.06\>200DNDI-VL-20980.22 ± 0.020.39 ± 0.07\>200DNDI-82190.60 ± 0.090.35 ± 0.03\>200AminopyrazolesDNDI-10440.17 ± 0.020.26 ± 0.06\>200DNDI-80120.22 ± 0.020.39 ± 0.07\>200OxaborolesDNDI-61480.63 ± 0.242.29 ± 0.42\>200DNDI-54211.76 ± 0.214.18 ± 0.1430.4 ± 0.87

3.2. Cross-resistance with current anti-leishmanial drugs {#sec3.2}
---------------------------------------------------------

The compounds were evaluated on a range of laboratory and field strains with different susceptibility profiles to the current drugs to gain additional information on their mode-of-action. The selected L. *infantum* strains were first evaluated against the current reference drugs ([Table 3](#tbl3){ref-type="table"}). DND*i* lead compounds showed no shift in susceptibility against any of the strains indicating that there is no obvious cross-resistance with the reference drugs ([Table 4](#tbl4){ref-type="table"}).Table 3***In vitro* drug-susceptibility profile of selected *L. infantum* strains with established resistance to the various reference drugs**. Results are expressed as the mean IC~50~ (μM) ± standard error of mean (SEM) and are based on three independent experiments with biological duplicates (n = 6). R = resistant, S = susceptible, I = intermediate.Table 3MEAN IC~50~SB^V^ (ΜG/ML EQ)SB^III^ (ΜG/ML EQ)MIL (ΜM)PMM (ΜM)*L. infantum*MEAN ± SEMMEAN ± SEMMEAN ± SEMMEAN ± **SEM**ITMAP26314 ± 25.5 ± 1.13.5 ± 0.995 ± 6L3034\>**777.3** ± 1.20.8 ± 0.315 ± 3LEM569529 ± 41.2 ± 0.30.8 ± 0.339 ± 19LEM515917 ± 32.1 ± 0.1**25** ± 385 ± 26LEM3323 CL4\>**77**\>**44**0.5 ± 0.161 ± 14LEM3323 CL4 PMM**77** ± 1**29** ± 80.9 ± 0.3**203** ± 49LEM3323 CL4 MIL\>**77**\>**4430** ± 649 ± 14[^2]Table 4***In vitro* susceptibility profile of the selected *L. infantum* strains against the various DND*i* lead compounds**. Results are expressed as the mean IC~50~ (μM) ± standard error of mean (SEM) and are based on three independent experiments with biological duplicates (n = 6).Table 4MEAN IC~50~NITROIMIDAZOLESAMINOPYRAZOLESOXABOROLESDNDI-0690DNDI-8219DNDI-VL-2098DNDI-1044DNDI-8012DNDI-6148DNDI-5421*L. infantum*MEAN ± SEMMEAN ± SEMMEAN ± SEMMEAN ± SEMMEAN ± SEMMEAN ± SEMMEAN ± SEMITMAP2630.33 ± 0.100.90 ± 0.500.40 ± 0.000.10 ± 0.040.09 ± 0.031.05 ± 0.291.03 ± 0.26L30340.05 ± 0.040.80 ± 0.000.90 ± 0.400.02 ± 0.010.04 ± 0.010.27 ± 0.110.89 ± 0.25LEM56950.01 ± 0.000.17 ± 0.080.21 ± 0.100.08 ± 0.080.01 ± 0.010.04 ± 0.030.02 ± 0.01LEM51590.17 ± 0.072.10 ± 0.501.70 ± 0.700.07 ± 0.030.09 ± 0.030.38 ± 0.220.52 ± 0.31LEM3323CL40.10 ± 0.072.20 ± 1.001.30 ± 0.200.14 ± 0.050.31 ± 0.150.27 ± 0.110.89 ± 0.25LEM3323CL4 PMM0.09 ± 0.022.10 ± 0.900.80 ± 0.500.30 ± 0.100.83 ± 0.220.69 ± 0.511.08 ± 0.31LEM3323CL4 MIL0.01 ± 0.010.80 ± 0.201.10 ± 0.000.04 ± 0.020.09 ± 0.050.03 ± 0.010.02 ± 0.01

3.3. Time-to-kill {#sec3.3}
-----------------

To first monitor the evolution of infection and amastigote burdens over the 15-day culture time, infection ratios based on the average number of amastigotes per cell (100 cells counted) of the selected *L. infantum* and *L. donovani* strains were determined every 24 h ([Fig. S1](#appsec1){ref-type="sec"}). The infection was stable over the total 15-day period with a peak after 144 h for both strains. All the compounds including the reference compounds reached a TTK within the 15 days of exposure ([Table 5](#tbl5){ref-type="table"}) with the aminopyrazoles being slower in fully eliminating intracellular *L. donovani* amastigotes. The nitroimidazoles cleared parasites faster as compared with the reference compounds. A short TTK was also observed for MIL but this was associated with high cytotoxicity after 96h of exposure. No cytotoxicity was noted with any of the DND*i* lead compounds.Table 5**Time-to-kill (TTK) defined in hours (h) for both *L. infantum* and *L. donovani* for the selected reference and DND*i* lead compounds**. Results are expressed as the mean and standard error of mean (SEM), results are based on two independent experiments with biological duplicates (n = 4).Table 5SeriesCompoundConcentration 5\*IC~50~ (μM)*L. infantumL. donovani*TTK (h)TTK (h)Reference drugsMIL207296PMM250168168Sb^V^77288288AmB5192192NitroimidazolesDNDI-069014896DNDI-VL-209817248DNDI-8219314496AminopyrazolesDNDI-10441192\>360DNDI-80121.5120\>360OxaborolesDNDI-61487^a^240ndDNDI-542115168240[^3]

3.4. *In vivo* efficacy in the early curative hamster model {#sec3.4}
-----------------------------------------------------------

Dose-titrations were performed against *L. infantum* to determine the potency of each compound ([Table 6](#tbl6){ref-type="table"}). Overall, nitroimidazoles showed excellent (\>90%) reduction of parasite load in the major target organs at a comparatively lower dose range than MIL. Aminopyrazoles and oxaboroles achieved reductions of organ burdens comparable to MIL. One compound of each lead series was subsequently selected for evaluation in the early curative model against *L. donovani*, fully confirming the excellent efficacy ([Table 7](#tbl7){ref-type="table"}).Table 6**Percentage reduction of amastigote burdens in liver, spleen and bone-marrow after a 5-day oral treatment with DND*i* lead compounds in the early curative *L. infantum* model in the hamster**. Results are expressed as percentage reduction and are based on one experiment with five animals per group. Treatment was given once a day (SID) or twice a day (BID).Table 6*L. Infantum*Dose% Reduction% Reduction% ReductionSeriesCompoundmg/kg/dayLiverSpleenBone-marrowReferenceMiltefosine40 SID97.999.697.3NitroimidazolesDNDI-069012.5 BID\
12.5 BID[a](#tbl6fna){ref-type="table-fn"}96.4\
99.597.5\
99.496.5\
96.86.25 BID\
6.25 BID[a](#tbl6fna){ref-type="table-fn"}92.6\
91.086.3\
91.686.7\
73.312.5 SID65.869.751.6DNDI-VL 209850 SID10010010025 SID10099.999.712.5 SID99.098.794.0DNDI-821925 BID\
25 BID[a](#tbl6fna){ref-type="table-fn"}87.6\
98.477.7\
99.268.8\
97.012.5 BID25.19.705.00AminopyrazolesDNDI-104450 BID97.198.678.225 BID99.899.798.512.5 BID96.594.749.8DNDI-801250 BID99.099.893.825 BID93.792.562.512.5 BID80.843.032.6OxaborolesDNDI-614850 BID10099.999.425 BID98.398.293.612.5 BID89.487.381.850 SID98.697.289.4DNDI-542150 BID99.498.593.425 BID97.395.492.6[^4]Table 7**Percentage reduction of amastigote burdens in liver, spleen and bone-marrow after a 5-day oral treatment with of the DND*i* lead compounds in the early curative *L. donovani* model in the hamster.** Results are expressed as percentage reduction and are based on one experiment with five animals per group. Treatment was given once a day (SID) or twice a day (BID).Table 7*L. donovaniIn vivo* effectDose% Reduction% Reduction% ReductionSeriesCompoundmg/kg/dayLiverSpleenBone-marrowReferenceMiltefosine40 SID98.499.397.3NitroimidazoleDNDI-069025 BID99.910099.912.5 BID99.899.9100AminopyrazoleDNDI-104450 BID96.397.766.925 BID92.694.588.3OxaboroleDNDI-614850 BID99.398.683.425 BID93.290.392.8

4. Discussion {#sec4}
=============

None of the current VL treatments is ideal as most of them require long treatment and are not devoid of toxicity issues, such as cardiac arrhythmias for Sb^V^ ([@bib6], [@bib37], [@bib11]), teratogenicity for MIL ([@bib33]), nephrotoxicity and ototoxicity for PMM ([@bib18]), and nephrotoxicity and myocarditis for conventional AmB ([@bib7]). Much better tolerated and more efficacious, the liposomal formulation of AmB has now been positioned as first-line therapy ([@bib35]), despite its high cost and the need to maintain a cold chain below 25 °C ([@bib4]). Adverse effects trigger poor treatment compliance which enhances the incidence of treatment failures and the risk of drug resistance development ([@bib33]). With regard to the latter, Sb^V^ has lost efficacy in hyperendemic regions in India and parts of Nepal ([@bib33]) and MIL increasingly faces treatment relapses ([@bib34]) but still with low incidence of intrinsic drug resistance ([@bib3], [@bib14]). No clinical resistant strains have yet been reported for PMM that is mostly used in combination therapy, however, resistance selection could be achieved alarmingly fast in the laboratory ([@bib14]).

In response to the pressing need for new drugs, DND*i* has selected three new lead series showing high efficacy against *Leishmania*. Representatives of each series were highly potent both *in vitro* and *in vivo* against the two VL species tested, *L. infantum* and *L. donovani*. When tested against a panel of *L. infantum* strains with different drug-susceptibility profiles, including clinical isolates with a Sb^V^--- and MIL-resistant background and laboratory selected MIL- and PMM-resistant strains, no cross-resistance was detected which implies that these compounds will likely have a mode-of-action that is different from the currently used antileishmanial drugs and could therefore be included in combination therapies. Co-administration or combination is now highly recommended by the WHO as it increases the chances of shortening treatment duration, lowering the costs and improving efficacy in complicated cases, such as in HIV co-infected or other immunocompromised patients. All these factors could also delay the emergence of drug-resistant parasites and increase the lifespan of the drugs ([@bib32]). Practical examples of combination treatment are the co-administration of AmB and MIL reducing the MIL treatment from 28 to 7 days, and the combination of PMM and MIL ([@bib36]). It was recently demonstrated that the induction of resistance *in vitro* and *in vivo* was markedly delayed when MIL and PMM were used simultaneously ([@bib16]).

To gain further insight into the antileishmanial efficacy of the lead series, the TTK assay evaluated the cidal capacity and dynamics of the compounds on the intracellular amastigote stage of the parasite ([@bib19]), providing insight whether the compounds are static (inhibiting growth) or cidal (ability to kill). Cidal versus static experiments are mostly used in the antibacterial field ([@bib20]) but have also been used more recently to study trypanocidal activity ([@bib24], [@bib8]). The reference compounds exerted cidal activity against both *Leishmania* species within the 15 days of exposure when tested at a 5 × IC~50~ concentration. MIL exhibited the shortest TTK of 72h for *L. infantum* and 96h for *L. donovani*, but with host cell cytotoxicity within 96h of drug exposure. For the nitroimidazoles, a very short TTK was observed (\<96h) for both species without any cytotoxicity. These observations are in line with a previously defined TTK of 48h for VL-2098 against *L. donovani* in J774 cells ([@bib12]). The oxaboroles showed TTKs comparable to the reference compounds ([Table 5](#tbl5){ref-type="table"}) but their speed of cidal activity was slower against *Leishmania* as compared to *T. brucei* (\<24h) which may relate to the extracellular nature of trypanosomes ([@bib17], [@bib38]). The aminopyrazoles showed good cidal activity against *L. infantum* (≤192h) but could not fully eliminate all intracellular *L. donovani* amastigotes (\>320h). This difference might reflect limited *in vitro* susceptibility differences between the two reference laboratory species but does not necessarily translate to the *in vivo* situation where excellent efficacy is demonstrated. It is worth noticing that the aminopyrazoles are still in lead optimization phase and new, more potent compounds are currently being evaluated.

In conclusion, the newly selected DND*i* lead series show great potential in view of their selective potency *in vitro* and *in vivo*, the lack of any cross-resistance with the current antileishmanial drugs and the cidal dynamics against both *L. donovani* and *L. infantum*. As such, the lead compounds could potentially be applied both in single and combination therapies. The clear cidal effects also offer perspectives in terms of a lowered risk of drug resistance and shorter treatment schedules.

Appendix A. Supplementary data {#appsec1}
==============================
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[^1]: Resistant (R) and intermediately resistant (I) phenotypes are highlighted in bold.

[^2]: Resistant (R) and intermediately resistant (I) phenotypes are highlighted in bold.

[^3]: nd: not done; ^a^ tested at about 10x IC~50~.

[^4]: Repeat experiment using a different batch.
